• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

9.55 EUR+5.18 %21.8. klo 18.29
5,671 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.18 %
-5.63 %
+6.70 %
-15.86 %
-32.75 %
-28.20 %
+213.11 %
+64.66 %
-98.42 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
77.11M EUR
Turnover
128.04K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
17.08.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
ShowingAll content types

Forum discussions
Thank you for the notice, @t14! The press releases should be available under the English sections “NEWS & EVENTS → News” and “INVESTORS → Releases”. Perhaps there was some technical glitch this morning, but they are visible there now, at least. Due to our international business, ...
15 hours ago
by Mikko Karvinen, Nexstim Oyj
51
This looks good, except for the share price. In H1/2026, revenue was €5.2M. At the end of H1, there were 7 undelivered orders, i.e., approximately €2.1M, and since then, there have been announcements for 18 units, i.e., approximately €5.4M. In addition, there is a €0.4M revenue recognition...
16 hours ago
by Matti Kukkaro
27
Weckroth likely doesn’t know how hardware sales will perform at the end of the year. Or do you believe he does, and are you drawing conclusions from that? He still has 134,000 shares left, which is more than anyone on this forum. Noise.
yesterday
20
A long-standing European client is upgrading their current system to NBS 6. There’s a nice level of activity in terms of orders, and personally, I’m not worried about the sales of Kakkonen or Weckroth.
20 hours ago
by Timustaja
17
A new research report once again confirms the strength of personalized and measurable stimulation. In other words, exactly the kind of higher-quality treatment that Nexstim has been talking about. https://www.hcplive.com/view/lower-tms-intensity-correlates-depression-improvement ...
20 hours ago
by AccionHombre
13
Subscribed. Let it come from every corner, as long as it comes. It was easy to notice on X. We are now on par with last year’s sales. Growth is inevitable.
19 hours ago
by Tee
10
Has the same amount of equipment been sold globally since this morning’s trading as was sold in total during the whole of last year?
20 hours ago
by Umpi
6
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release21.08.2026 klo 09.00

Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer

Nexstim
Regulatory press release20.08.2026 klo 13.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Press release19.08.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from New US Customer

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Nexstim H1'26: Brainlab potential to be weighed later this year
Research17.08.2026 klo 10.09 by
Antti Siltanen

Nexstim H1'26: Brainlab potential to be weighed later this year

Concrete evidence of the Brainlab collaboration's potential will be available during the rest of the year.

Nexstim
Regulatory press release14.08.2026 klo 09.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2026 (UNAUDITED)

Nexstim
Press release11.08.2026 klo 09.00

Notice of Nexstim Plc’s Half-Year Report H1 2026

Nexstim
Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate
Analyst Comment11.08.2026 klo 09.25 by
Antti Siltanen

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

We expect the dip in recurring revenue to have weighed on earnings.

Nexstim
Press release31.07.2026 klo 13.00

Finnish Private Clinic Group Orders Additional Nexstim NBS 6 System

Nexstim
Regulatory press release20.07.2026 klo 13.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Press release17.07.2026 klo 09.00

Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Nexstim
Press release15.07.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from a Neurology Clinic in the United States

Nexstim
Nexstim received another order for ten NBS 6 systems
Analyst Comment15.07.2026 klo 09.01 by
Frans-Mikael Rostedt

Nexstim received another order for ten NBS 6 systems

The second order for ten systems within a month indicates the rapid scaling of the distribution partnership.

Nexstim
Press release14.07.2026 klo 09.00

Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor

Nexstim
Press release10.07.2026 klo 09.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026 klo 09.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim
Press release07.07.2026 klo 09.00

Nexstim Receives Malaysian Authorization for Commercial Distribution of NBS System 6

Nexstim
New NBS 6 system order for Nexstim from USA
Analyst Comment06.07.2026 klo 09.17 by
Atte Riikola

New NBS 6 system order for Nexstim from USA

This is a new customer for the company

Nexstim
Press release03.07.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from New Customer in the United States

Nexstim
Significant one-time order for Nexstim
Analyst Comment12.06.2026 klo 09.28 by
Antti Siltanen

Significant one-time order for Nexstim

The one-time order for ten systems strengthens our confidence in this year's growth estimates.

Nexstim
Press release11.06.2026 klo 09.00

Nexstim Receives Order for Ten NBS 6 Systems from Distributor

Nexstim